https://pharminent.com/market-access/market-access-intelligence-weekly-digest-july-3-2026/ 2026-07-03T19:32:11Z Pharminent en MARKET ACCESS INTELLIGENCE • Weekly Digest • July 3, 2026 2026-07-03T19:32:09Z Blog https://pharminent.com/biontech-held-buyer-talks-over-four-german-sites-set-to-close-handelsblatt-reports/ 2026-07-03T19:13:30Z Pharminent en BioNTech Held Buyer Talks Over Four German Sites Set to Close, Handelsblatt Reports 2026-07-03T19:13:26Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-july-3-2026/ 2026-07-03T18:35:48Z Pharminent en Strategic News Watch • July 3, 2026 2026-07-03T15:49:19Z Blog https://pharminent.com/rare-disease-gene-therapy/rare-disease-gene-therapy-digest-july-2-2026/ 2026-07-02T20:42:50Z Pharminent en Rare Disease & Gene Therapy Digest • July 2, 2026 2026-07-02T20:42:48Z Blog https://pharminent.com/roches-divarasib-beats-amgen-and-bms-head-to-head-in-phase-3-kras-lung-cancer-trial/ 2026-07-02T17:46:58Z Pharminent en Roche's Divarasib Beats Amgen and BMS Head-to-Head in Phase 3 KRAS Lung Cancer Trial 2026-07-02T17:46:58Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-july-2-2026/ 2026-07-02T16:15:11Z Pharminent en Strategic News Watch • July 2, 2026 2026-07-02T16:15:10Z Blog https://pharminent.com/biogen-bets-on-tau-at-aaic-diranersen-phase-2-celia-data/ 2026-07-02T14:23:25Z Pharminent en Biogen Bets on Tau at AAIC: Diranersen Phase 2 CELIA Data 2026-07-02T14:23:25Z Blog https://pharminent.com/novartis-receives-european-commission-approval-for-itvisma-for-spinal-muscular-atrophy/ 2026-07-03T14:05:48Z Pharminent en Novartis receives European Commission approval for Itvisma for spinal muscular atrophy 2026-07-02T13:32:11Z Blog https://pharminent.com/az-forges-ever-closer-ties-with-chinas-cspc-pharma/ 2026-07-03T14:06:19Z Pharminent en AZ forges ever-closer ties with China's CSPC Pharma 2026-07-02T11:59:18Z Blog https://pharminent.com/roches-kras-drug-tops-its-rivals-in-lung-cancer-trial/ 2026-07-02T17:22:00Z Pharminent en Roche's KRAS drug tops its rivals in lung cancer trial 2026-07-02T10:11:25Z Blog https://pharminent.com/insilico-medicine-takeda-partner-on-ai-driven-drug-discovery/ 2026-07-03T14:07:43Z Pharminent en Insilico Medicine, Takeda partner on AI-driven drug discovery 2026-07-02T09:57:47Z Blog https://pharminent.com/neuromarket-pulse/neuromarket-pulse-weekly-neuroscience-competitive-intelligence-july-1-2026/ 2026-07-01T21:09:59Z Pharminent en NeuroMarket Pulse • Weekly Neuroscience Competitive Intelligence • July 1, 2026 2026-07-01T21:09:57Z Blog https://pharminent.com/fda-selects-seven-for-precheck-pilot-to-advance-drug-manufacturing/ 2026-07-01T17:54:21Z Pharminent en FDA Selects Seven for PreCheck Pilot to Advance Drug Manufacturing 2026-07-01T17:54:21Z Blog https://pharminent.com/ipsen-acquires-memo-therapeutics-for-up-to-e700m-in-second-deal-in-three-days/ 2026-07-01T17:53:24Z Pharminent en Ipsen Acquires Memo Therapeutics for Up to €700M in Second Deal in Three Days 2026-07-01T17:53:20Z Blog https://pharminent.com/manufacturing-intelligence/manufacturing-intelligence-weekly-digest-july-1-2026/ 2026-07-01T17:40:59Z Pharminent en Manufacturing Intelligence • Weekly Digest • July 1, 2026 2026-07-01T17:40:57Z Blog https://pharminent.com/decoding-medicare-advantage-coding-intensity/ 2026-07-02T14:45:47Z Pharminent en Decoding Medicare Advantage Coding Intensity 2026-07-01T16:15:00Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-july-1-2026/ 2026-07-01T16:14:14Z Pharminent en Strategic News Watch • July 1, 2026 2026-07-01T16:14:12Z Blog https://pharminent.com/ipsen-to-buy-swiss-biotech-memo-therapeutics-in-potential-800m-deal/ 2026-07-01T21:27:01Z Pharminent en Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M deal 2026-07-01T13:51:27Z Blog https://pharminent.com/alzecure-enters-collaboration-agreement-with-quantumcell-aps-for-neurorestore-project/ 2026-07-02T13:21:26Z Pharminent en AlzeCure enters collaboration agreement with QuantumCell ApS for NeuroRestore project 2026-07-01T13:35:53Z Blog https://pharminent.com/eli-lilly-and-regeneron-among-7-companies-picked-for-fda-precheck-pilot-program/ 2026-07-01T21:24:37Z Pharminent en Eli Lilly and Regeneron among 7 companies picked for FDA PreCheck pilot program 2026-07-01T13:22:08Z Blog https://pharminent.com/ean-2026-real-world-data-supports-safety-and-efficacy-of-abbvies-vyalev-in-parkinsons/ 2026-07-01T18:02:13Z Pharminent en EAN 2026: Real-world data supports safety and efficacy of AbbVie's Vyalev in Parkinson's 2026-07-01T12:50:20Z Blog https://pharminent.com/sarepta-secures-early-2027-fda-decision-for-duchenne-drugs-pushing-past-confirmatory-fail/ 2026-07-01T21:24:47Z Pharminent en Sarepta secures early 2027 FDA decision for Duchenne drugs, pushing past confirmatory fail 2026-07-01T11:56:42Z Blog https://pharminent.com/fda-clears-orcas-cell-therapy-tregzi-for-gvhd/ 2026-07-02T13:24:25Z Pharminent en FDA clears Orca's cell therapy Tregzi for GvHD 2026-07-01T10:40:46Z Blog